- Investing Ideas
- /
- Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Danish Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
6
Companies with a Value score of at least 3, ordered by Value score
6 companies
H. Lundbeck
Market Cap: DKK 27.0b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN B
DKK 28.00
7D
-5.1%
1Y
-16.4%
Genmab
Market Cap: DKK 77.7b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,225.00
7D
-0.7%
1Y
-40.5%
Bavarian Nordic
Market Cap: DKK 11.3b
Develops, manufactures, and supplies life-saving vaccines.
BAVA
DKK 145.85
7D
4.1%
1Y
-5.0%
Novo Nordisk
Market Cap: DKK 1.9t
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
NOVO B
DKK 420.30
7D
-3.2%
1Y
-52.2%
H. Lundbeck
Market Cap: DKK 27.0b
Engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
HLUN A
DKK 24.00
7D
-3.4%
1Y
-15.3%
ALK-Abelló
Market Cap: DKK 31.1b
Operates as an allergy solutions company in Europe, North America, and internationally.
ALK B
DKK 140.60
7D
2.6%
1Y
9.3%